Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.50 |
| ▸ | CCR8 | P51685 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CCR5 | P51681 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582442 | 0.78 | CCR1 (0.46) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL31276857 | 0.78 | CCR1 (0.46) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL2696188 | 0.77 | PSMD14 (0.62) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL7441724 | 0.77 | HSP90AA1 (0.54) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL15007502 | 0.77 | KDM4E (0.48) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL1611156 | 0.77 | NR4A2 (0.53) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL364531 | 0.77 | KDM4E (0.57) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL1148265 | 0.77 | CCR1 (0.50) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL7450182 | 0.77 | CCR1 (0.55) | CCR1CCR8HTTSMN1; SMN2LMNA | |
| SCHEMBL10880120 | 0.77 | CCR1 (0.46) | CCR1CCR8HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788347-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-15 | — | — | EP | disclosed |
| US-8742098-B2 | Inhibitors of Bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742098-B2 | Inhibitors of Bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742098-B2 | Inhibitors of Bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| WO-2013083666-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083666-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150360-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150360-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150360-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1390364-A1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | Wyeth (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| WO-2002096906-A1 | ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH (US) | 2002-12-05 | — | — | WO | disclosed |
| US-4812471-A | Hypoglycemic 5-(isoxazolyl or isothiazolyl)-oxazolidine-2,4-diones | PFIZER INC. (US) | 1989-03-14 | — | — | US | disclosed |
| US-4753956-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4689336-A | Hypoglycemic 5-substituted oxazolidine 2,4-diones | PFIZER INC. (US) | 1987-08-25 | — | — | US | disclosed |
| US-4565820-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150360-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CCR1 1062/4885CCR8 2360/4885HTT 4427/4885 |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | CCR1 593/4885CCR8 519/4885HTT 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.